Curis (CRIS) Total Liabilities (2010 - 2026)
Curis' (CRIS) quarterly Total Liabilities came in at $17.0 million in Q1 2026, down 63.04% YoY from $45.9 million in Q1 2025, and up 17.06% on a QoQ basis from $14.5 million in Q4 2025.
Curis (CRIS) Total Liabilities (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Total Liabilities data on file, last reported at $17.0 million in Q1 2026.
- Quarterly Total Liabilities fell 63.04% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (down 63.04% YoY) and the FY2025 annual result came in at $14.5 million, down 69.31% from the prior year.
- Total Liabilities grew to $17.0 million in Q1 2026, from $14.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $67.1 million in Q3 2022 to a low of $14.5 million in Q4 2025.
- A 5-year average of $50.6 million and a median of $52.6 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities retreated 2.81% — and 2025, when it tumbled 69.31%.
- Tracing CRIS's Total Liabilities over 5 years: stood at $62.3 million in 2022, then dropped by 7.52% to $57.6 million in 2023, then declined by 17.96% to $47.3 million in 2024, then plunged by 69.31% to $14.5 million in 2025, then gained by 17.06% to $17.0 million in 2026.
- The last three Total Liabilities figures came in at $17.0 million (Q1 2026), $14.5 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 10.03 Bn |
| 10 | Curis | 3.42 Mn | -2.20 Mn | - | 14.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.98 Mn |
| Dec 31, 2025 | 14.50 Mn |
| Sep 30, 2025 | 42.33 Mn |
| Jun 30, 2025 | 43.22 Mn |
| Mar 31, 2025 | 45.93 Mn |
| Dec 31, 2024 | 47.26 Mn |
| Sep 30, 2024 | 51.21 Mn |
| Jun 30, 2024 | 51.11 Mn |
| Mar 31, 2024 | 52.56 Mn |
| Dec 31, 2023 | 57.61 Mn |
| Sep 30, 2023 | 60.38 Mn |
| Jun 30, 2023 | 58.08 Mn |
| Mar 31, 2023 | 57.95 Mn |
| Dec 31, 2022 | 62.30 Mn |
| Sep 30, 2022 | 67.11 Mn |
| Jun 30, 2022 | 66.79 Mn |
| Mar 31, 2022 | 64.77 Mn |
| Dec 31, 2021 | 71.59 Mn |
| Sep 30, 2021 | 69.18 Mn |
| Jun 30, 2021 | 68.72 Mn |